This announcement is a separate document:
6-K: European Commission Approves Expanded Age Indication for Gsk's Arexvy, The First Respiratory Syncytial Virus (Rsv) Vaccine for Adults Aged 50-59 at Increased Risk
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.